WuXi Biologics Reports Double-Digit Growth in First Half of 2026

The company’s adjusted net profit climbed 38.6% to RMB 3.9 billion, bolstered by improved operating leverage and productivity gains through its internal business system. Despite foreign exchange headwinds, the firm’s gross profit margin reached 46.2%, reflecting a 350 basis point improvement over the previous year. A key driver for this performance was the addition of 123 new organic integrated projects, a 43% increase compared to the same period in 2025.

Technological integration remains central to the group's strategy. The WuXia™ TrueSite platform, launched in late 2025, has been implemented across 70 projects, enabling faster development timelines and lower costs for complex modalities. Meanwhile, the firm’s backlog has grown to US$ 25.1 billion, with near-term revenue visibility strengthening as the company prepares for 64 process performance qualification campaigns scheduled through 2027. CEO Chris Chen noted that the company is well-positioned to capitalize on digital advances in drug discovery while continuing to expand its global manufacturing footprint in China, the U.S., and Europe.